Myhep All Tablets ( Sofosbuvir 400mg and Velpatasvir 100mg Tablets - Mylan)

We are manfacturer, trader & supplier of  Myhep-All tablets.

Our Myhep All Tablet (Sofosbuvir 400mg and Velpatasvir 100mg Tablet-Mylan) is the fixed dosage blend of the two generally utilized anti-viral specialists. Velpatasvir and Sofosbuvir are straightforwardly acting anti-viral specialists which are engaged with the therapy of persistent hepatitis C viral disease. Sofosbuvir is typically blended with other anti-viral specialist for displaying the unmistakable impacts. The provided Myhep All Tablet (Sofosbuvir 400mg and Velpatasvir 100mg Tablet-Mylan) is FDA, which is utilized in HCV treatment. It ought to be utilized in genotype IV, I, III, VI, II or V hepatitis C infections. 

Myhep-All is the fixed dose combination of these two most widely used anti-viral agents. Sofosbuvir & Velpatasvir are directly acting anti-viral agents which are involved in the treatment of chronic hepatitis C viral infection. Sofosbuvir is usually combined with other anti-viral agent for exhibiting the prominent effects. Myhep-All is the FDA approved product, which is used in chronic HCV condition. Myhep-All should be used in genotype I, II, III, IV, V or VI associated hepatitis C viral infections.

Examine the patients thoroughly, before initiating the treatment with HCV anti-viral agents. Care should be taken while using HCV medication in patients with HCV/HIV-1co infections, in this case HBV reactivation occurs. Myhep-All tablets are recommended for chronic condition of hepatitis C viral infection related to genotype 1, 2, 3, 4, 5 or 6. The dosing of Myhep-All; The usual recommended dose of Myhep-All is, one tablet should be administered orally as a single dose. Myhep-All tablet consist of 100mg of Velpatasvir & 400mg of Sofosbuvir

mechanism of actions

Sofosbuvir is a NS5B protein inhibitor, protein is essential for viral production. Sofosbuvir is a prodrug form, which get converted into active uridine triphosphate form which is required for anti-viral activity. This dynamic active moiety is get inserted into HCV RNA with the help of NS5B polymerase and leads as chain eliminator. Velpatasvir is pharmacologically acts as NS5A inhibitor; this protein is required for HCV viral production. Velpatasvir is involved its action in viral production process

Dosage and Administration

Patients suffered with compensated cirrhosis or without cirrhosis; One tablet of Myhep-All should be administered orally as once daily over period of 12 weeks. Patients suffered with decompensated cirrhosis; One Myhep-All tablet should be combined with weight based ribavirin by administering with food for 12 hours. The dose of ribavirin should be calculated for the patients; Patient with <75kg of body weight, the recommended dose of ribavirin is 1000mg administered as twice daily. Patient with at least 75kg of body weight, recommended dose of ribavirin is 1200mg administered as twice daily. For both renal & hepatic impaired patients; Myhep-All tablets dosage adjustment should not be recommended.

The maximum plasma concentration of Myhep-All is;
Sofosbuvir at 0.5 to 1 hour & Velpatasvir at 3 hours Food does not affect the absorption of Myhep-All The Myhep-All tablet is highly bound to human plasma protein is; Sofosbuvir 61 to 65% & Velpatasvir by >99.5%

The blood plasma ratio of;

Sofosbuvir 0.7 & Velpatasvir 0.52 to 0.67. The Myhep-All metabolism is majorly occurs in liver; sofosbuvir by cathepsin A or carboxyl esterase 1 & Velpatasvir by CYP2B6, CYP2C8 or CYP3A4.

Myhep-All excretion occurs via;

Sofosbuvir by urine (80%), feces (14%) & exhaled air (2.5%) & Velpatasvir by urine (88%) & feces (6.6%) The half lives of Myhep-All;

UNFAVORABLE EFFECTS 

Serious bradycardia occurs due to concomitant use of Myhep All with amiodarone. Insomnia Irritability Headache Fatigue Nausea Asthenia

LAB ABNORMALITIES

Lipase elevation Elevation of creatine kinase Elevation of bilirubin levels

POST MARKETING EFFECTS

Myhep all is manufactured and marketed by Mylan ltd

Product details